© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Jul 24, 2015, the consensus forecast amongst 36 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 31, 2009. The previous consensus forecast advised that AstraZeneca plc would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
Share price forecast information is not available for AstraZeneca PLC. View Full Financials
In 2014, AstraZeneca PLC reported a dividend of 2.77 USD, which represents a 208.17% increase over last year. The 31 analysts covering the company expect dividends of 2.81 USD for the upcoming fiscal year, an increase of 1.17%. View Full Financials
|Div growth (TTM)||+208.17 %|
On Apr 24, 2015, AstraZeneca plc reported 1st quarter 2015 earnings of 1.08 per share. This result was in line with the consensus of the 10 analysts following the company and under-performed last year's 1st quarter results by 7.69 %.
The next earnings announcement is expected on Jul 30, 2015. View Full Interim Financials
|Average growth rate||+1.59 %|
AstraZeneca plc reported annual 2014 earnings of 4.28 per share on Feb 05, 2015. View Full Annual Financials
|Average growth rate||-9.98 %|
AstraZeneca PLC had 1st quarter 2015 revenues of 6.06bn. This bettered the 5.98bn consensus of the 12 analysts covering the company. This was 5.60 % below the prior year's 1st quarter results. View Full Interim Financials
|Average growth rate||-1.31 %|
AstraZeneca PLC had revenues for the full year 2014 of 26.10bn. This was 1.49% above the prior year's results. View Full Annual Financials
|Average growth rate||-5.59 %|